Skip to content

Skin irritation and sensitization due to intimate lubricant

GRC161-24 Dermatologist-supervised assessment of primary and cumulative irritation potential, skin sensitization potential for investigational product intimate lubricant

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-35x4fz7
Enrollment
Unknown
Registered
2024-08-26
Start date
2024-05-22
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patch Tests

Interventions

Controlled, single-center clinical trial to evaluate primary and accumulated skin irritation and skin sensitization through maximized and controlled applications of an investigational intimate lubrica

Sponsors

Kosmoscience Ciência e Tecnologia Cosm Imp Exp LTDA
Lead Sponsor
Kosmoscience Ciência e Tecnologia Cosm Imp Exp LTDA
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Healthy research participant; age range between 18 and 70 years old; gender: female and male; phototype: I to IV. fitzpatrick classification; agreement not to wet the area during the entire test period; understand the test procedures and agree to adhere to the study requirements; absence of inflammatory dermatoses or tattoos at the application site; signing of the Free and Informed Consent Form (TCLE)

Exclusion criteria

Exclusion criteria: Pregnancy, lactation; presence of localized or generalized dermatological diseases; presence of active inflammatory dermatoses in the test region; frequent exposure to the sun or tanning beds; have participated in an allergenicity study within a period of less than four weeks from the start of the study; research participants with a history of allergy to the material used in the study; history of atopy; history of pathologies aggravated or triggered by ultraviolet radiation; people with immunodeficiencies; forecast of intense sun exposure or tanning session during the study period; anticipated bathing in the sea, swimming pool or sauna during the study; research participants who practice water sports; dermographism; use of the following topical or systemic medications: immunosuppressants, antihistamines, non-steroidal anti-inflammatory drugs, and corticosteroids up to 2 weeks before selection; treatment with acid vitamin A and/or its derivatives orally or topically up to 1 month before the start of the study; aesthetic and/or dermatological body treatment up to 3 weeks before selection; expected vaccination during the study or up to 3 weeks before the study; any condition not mentioned above that, in the opinion of the investigator, may compromise the evaluation of the study; history of lack of adherence or unwillingness to adhere to the study protocol; professionals directly involved with the research center and sponsor in carrying out this protocol and their families; be participating in another study at the time; any condition that, in the researcher's opinion, could compromise the study (describe)

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: Evaluate the potential for Primary Dermal Irritability, Accumulated Dermal Irritability and Dermal Sensitization of products through the application of Patch Test, proving the product's safety for topical use

Secondary

MeasureTime frame
No secondary outcomes are expected

Countries

Brazil

Contacts

Public ContactAna Tabarini Alves Pinheiro

Kosmoscience Ciência e Tecnologia Cosmética Importação Exportação LTDA

analucia@kosmoscience.com+55(19)40628689

Outcome results

None listed

Source: REBEC (via WHO ICTRP)